NorthSea Therapeutics B.V. announced that it has raised $80 million in a round of funding co-led by new investor Ysios Capital Partners, SGEIC, S.A.U. and Forbion Growth Opportunities Fund I, a fund managed by returning investor Forbion Capital Partners B.V. on December 17, 2021. The transaction also involved participation from new investor Hercules Capital, Inc., returning investors, Forbion Capital Fund II, a fund managed by Forbion Capital Partners B.V., venBio LLC, Novo Seeds, a fund managed by Novo Holdings A/S, Sofinnova Investment, Inc., BioGeneration Ventures B.V., and New Science Ventures, LLC. As part of the transaction, Jordi Xiol of Ysios Capital Partners, SGEIC, S.A.U. and Dirk Kersten of Forbion Capital Partners B.V. will join the board of directors of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.95 USD | -0.05% | +3.84% | +13.68% |
Apr. 03 | KARL STORZ SE & Co. KG entered into an agreement to acquire Asensus Surgical, Inc. for $100 million. | CI |
Mar. 26 | Bluebird bio to Restate Financial Statements; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.68% | 3.04B | |
+31.41% | 12.02B | |
+2.96% | 1.42B | |
-8.46% | 1.23B | |
+0.35% | 611M | |
+33.12% | 565M | |
-14.45% | 558M | |
+35.09% | 493M | |
-4.17% | 493M | |
+3.90% | 305M |
- Stock Market
- Equities
- HTGC Stock
- News Hercules Capital, Inc.
- NorthSea Therapeutics B.V. announced that it has received $80 million in funding from a group of investors